Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

<p><strong>Aims</strong></p> <p>To evaluate 1,5‐anhydroglucitol (1,5‐AG) according to clinical outcomes and assess the effects of glucose‐ and blood pressure‐lowering interventions on change in 1,5‐AG levels in people with type 2 diabetes.</p> <p><strong...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Selvin, E, Wang, D, McEvoy, JW, Juraschek, SP, Lazo, M, Hamet, P, Cooper, ME, Marre, M, Williams, B, Harrap, S, Chalmers, J, Woodward, M
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Wiley 2019

Eitemau Tebyg

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
gan: Rahman, F, et al.
Cyhoeddwyd: (2019)

Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism
gan: Man Li, et al.
Cyhoeddwyd: (2017-06-01)

Data for serum 1,5 anhydroglucitol concentration in different populations
gan: Marciane Welter, et al.
Cyhoeddwyd: (2018-10-01)

The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus
gan: Haiying Xu, et al.
Cyhoeddwyd: (2024-10-01)

The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients
gan: Eduardo Moraes Leao Peixoto, et al.
Cyhoeddwyd: (2014-10-01)

The use of 1,5 anhydroglucitol level as a clinical test to differentiate subtypes of diabetes
gan: Owen, K, et al.
Cyhoeddwyd: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
gan: Ohkuma, T, et al.
Cyhoeddwyd: (2019)

Pemeriksaan 1,5-Anhydroglucitol, Suatu Hal Baru dalam Pemeriksaan Prediabetes
gan: Reza Febryan
Cyhoeddwyd: (2024-03-01)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
gan: Ha Yeong Yoo, et al.
Cyhoeddwyd: (2015-12-01)

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
gan: Huijuan Xu, et al.
Cyhoeddwyd: (2024-05-01)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
gan: Atkins, A, et al.
Cyhoeddwyd: (2017)

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
gan: Pal, A, et al.
Cyhoeddwyd: (2010)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
gan: Kamel Mohammedi, et al.
Cyhoeddwyd: (2021-01-01)

Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction
gan: Yijia Wang, et al.
Cyhoeddwyd: (2022-12-01)

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
gan: Thyparambil Aravindakshan Pramodkumar, et al.
Cyhoeddwyd: (2016-01-01)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
gan: Zoungas, S, et al.
Cyhoeddwyd: (2009)

1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
gan: V. V. Klimontov, et al.
Cyhoeddwyd: (2020-08-01)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
gan: Ji-Eun Lee
Cyhoeddwyd: (2015-06-01)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
gan: Patel, A, et al.
Cyhoeddwyd: (2008)

Lowering blood pressure reduces renal events in type 2 diabetes.
gan: de Galan, B, et al.
Cyhoeddwyd: (2009)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
gan: Perkovic, V, et al.
Cyhoeddwyd: (2013)

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus
gan: Masahiro Usui, et al.
Cyhoeddwyd: (2020-09-01)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
gan: Rådholm, K, et al.
Cyhoeddwyd: (2018)

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
gan: Gong Su, et al.
Cyhoeddwyd: (2020-05-01)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
gan: Woodward, M, et al.
Cyhoeddwyd: (2016)

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
gan: Kenji Tanaka, et al.
Cyhoeddwyd: (2021-08-01)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
gan: Mohammedi, K, et al.
Cyhoeddwyd: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
gan: Mohammedi, K, et al.
Cyhoeddwyd: (2017)

Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
gan: Jian Zhou, et al.
Cyhoeddwyd: (2021-03-01)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
gan: Hannah Seok, et al.
Cyhoeddwyd: (2015-04-01)

Evaluation of 1,5-Anhydroglucitol as a Biomarker for Type 2 Diabetes Mellitus in Patients without Overt Nephropathy
gan: Luiza Cristina Gobor, et al.
Cyhoeddwyd: (2021-10-01)

Detection of 1,5-anhydroglucitol as a Biomarker for Diabetes Using an Organic Field-Effect Transistor-Based Biosensor
gan: Hiroyuki Furusawa, et al.
Cyhoeddwyd: (2018-08-01)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
gan: Ben A. Kappel, et al.
Cyhoeddwyd: (2021-06-01)

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes
gan: Yun Shen, et al.
Cyhoeddwyd: (2020-01-01)

Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography
gan: Ruiyue Yang, et al.
Cyhoeddwyd: (2022-09-01)

Evaluation of serum 1,5-anhydroglucitol levels as hyperglycemic indicator in patients with newly diagnosed type 2 diabetes mellitus
gan: Ashok Vanagamudi, et al.
Cyhoeddwyd: (2022-01-01)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
gan: Mohammedi, K, et al.
Cyhoeddwyd: (2016)

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients
gan: Yijia Wang, et al.
Cyhoeddwyd: (2024-07-01)

1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation
gan: Huasu Zhu, et al.
Cyhoeddwyd: (2023-02-01)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
gan: Blomster, J, et al.
Cyhoeddwyd: (2017)